Brian I. Rini

Also affiliated with Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.1Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2386

Top 29%

0.694DataRank

Top 29%11 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Papers

Driven by 38 papers — median percentile 0. Top paper: “Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The Lancet(2020)10.1016/s0140-6736(20)31187-9

N/A

11.9DataRank · unranked

1804 citations

Toni K. Choueiri, Dimpy P. Shah, Yu Shyr, Samuel M. Rubinstein, Donna R. Rivera +95 more

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Annals of Oncology(2021)10.1016/j.annonc.2021.02.024

N/A

6.8DataRank · unranked

328 citations

Ali Raza Khaki, Trisha M. Wise‐Draper, Benjamin French, Conor Hennessy, Chih–Yuan Hsu +95 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial

Clinical Infectious Diseases(2020)10.1093/cid/ciaa1571

N/A

4.6DataRank · unranked

128 citations

Ananta Bangdiwala, Melanie R. Nicol, Caleb P Skipper, Katelyn A Pastick, Margaret L. Axelrod +30 more

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005445

N/A

2.7DataRank · unranked

69 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George +9 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

British Journal of Cancer(2020)10.1038/s41416-020-01041-x

N/A

2.6DataRank · unranked

90 citations

Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla +15 more

Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.03.019

N/A

0.848DataRank · unranked

20 citations

Michael B. Atkins, Toni K. Choueiri, Despina Thomaidou, Brad Rosbrook, M. Thakur +2 more

Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2386

Top 29%

0.694DataRank

Top 29%11 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial

BMJ Oncology(2024)10.1136/bmjonc-2023-000181

N/A

0.536DataRank · unranked

8 citations

Yu‐Wei Chen, Martin H. Voss, Bradley A. McGregor, Mehmet Asım Bilen, Marc‐Oliver Grimm +9 more

Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6565

Top 45%

0.406DataRank

Top 45%5 citations

Ana F. Best, Sacha Gnjatic, Andrea Denicoff, Grace Mishkin, Melissa Bowman +15 more

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Cancers(2022)10.3390/cancers14153830

N/A

0DataRank · unranked

18 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma

Current Oncology Reports(2022)10.1007/s11912-022-01196-1

N/A

0DataRank · unranked

16 citations

Brian I. Rini, Yu‐Wei Chen

Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4527

N/A

0DataRank · unranked

2 citations

Matthew D. Tucker, Landon C. Brown, Hesham Yasin, Kristin Kathleen Ancell, Andrew J. Armstrong +12 more

Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.364

N/A

0DataRank · unranked

0 citations

Matthew D. Tucker, Hesham Yasin, Kristin Kathleen Ancell, Nancy B. Davis, Scott M. Haake +8 more

Improved overall survival of metastatic cancers in the United States across all age groups in the immunotherapy era: Implications for considering elderly patients (age ≥ 75) for immune checkpoint inhibitors (ICIs).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12039

N/A

0DataRank · unranked

0 citations

Matthew D. Tucker, Hesham Yasin, Xingyi Guo, Xiao‐Ou Shu, Brian I. Rini +1 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

(2023)10.1158/1078-0432.c.6531354

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Data from Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)

(2023)10.1158/1078-0432.c.6531354.v1

Top 100%

0DataRank

Top 100%0 citations

Susan Halabi, Yingmiao Liu, Mark D. Starr, John C. Brady, Ivo Shterev +9 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Cancer Cell(2024)10.1016/j.ccell.2024.03.002

N/A

0DataRank · unranked

46 citations

Chris Labaki, Tejas Jammihal, Wanling Xie, Maxine Sun, Valisha Shah +19 more

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist(2025)10.1093/oncolo/oyaf138

N/A

0DataRank · unranked

0 citations

Neil J. Shah, Matthew T. Campbell, Naomi B. Haas, Ariel Ann Nelson, Moshe Chaim Ornstein +12 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0941

N/A

0DataRank · unranked

138 citations

Solange Peters, Orestis A. Panagiotou, Dimpy P. Shah, Nicole M. Kuderer, Chih–Yuan Hsu +40 more

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa064

N/A

0DataRank · unranked

40 citations

Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch +15 more

MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma

Molecular Metabolism(2020)10.1016/j.molmet.2020.01.011

N/A

0DataRank · unranked

28 citations

Daniel J. Silver, Venkateshwari Varadharajan, Renliang Zhang, C. Alicia Traughber, Christopher G. Przybycin +6 more

Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer

medRxiv(2020)10.1101/2020.04.29.20085738

N/A

0DataRank · unranked

14 citations

Kelli L. Boyd, Paula I. González-Ericsson, Cindy Lowe, Hunter M. Brown, Robert Hoffman +12 more

The effect of deep AR suppression with enzalutamide or apalutamide on endogenous glucocorticoids: Implications for adverse effects and development of combination therapies.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.17

N/A

0DataRank · unranked

0 citations

Mohammad Alyamani, Jianbo Li, Mona Patel, Michael Berk, Susan Taylor +8 more

Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages

Cell(2021)10.1016/j.cell.2021.04.038

N/A

0DataRank · unranked

377 citations

Nivedita Chowdhury, Scott M. Haake, Casey R. Ager, Vinson Wang, Lukas Vlahos +12 more

COVID-19 vaccination and breakthrough infections in patients with cancer

Annals of Oncology(2021)10.1016/j.annonc.2021.12.006

N/A

0DataRank · unranked

102 citations

Chris Labaki, Chih–Yuan Hsu, Ziad Bakouny, Nino Balanchivadze, Stephanie Berg +34 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation

Cell Reports(2021)10.1016/j.celrep.2021.109747

N/A

0DataRank · unranked

22 citations

Francis Enane, Rita Tohmé, Caroline Schuerger, Tomas Radivoyevitch, Yvonne Parker +7 more

Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma

Cancers(2021)10.3390/cancers13061475

N/A

0DataRank · unranked

16 citations

Anupama Reddy, Stephanie O. Dudzinski, Aaron R. Lim, Ayaka Sugiura, Rachel A. Hongo +26 more

Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma

European Urology(2021)10.1016/j.eururo.2021.12.003

N/A

0DataRank · unranked

13 citations

Akhilesh Mishra, Alana Christie, Tiffani McKenzie, Oreoluwa Onabolu, Nirmish Singla +12 more

Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.6566

Top 100%

0DataRank

Top 100%0 citations

Ana F. Best, Alok A. Khorana, Steven A. Pergam, Grace Mishkin, Melissa Bowman +8 more

Brian I. Rini

Indexed papers

Top data-sharing exemplar

Papers